多隻生物股逆市再破頂 康方生物(09926.HK)反覆續漲逾半成高見37.45元
將於下周一掛牌的兩隻醫藥相關股海吉亞醫療(06078.HK)及康基醫療(09997.HK)招股反應熱烈,其中公開發售分別獲逾600-980倍超購,認購一手中籤率僅約9%。多隻影子生物股今早股價再破頂創上市新高,包括藥明生物(02269.HK)及百濟神州(06160.HK)分別高見150.6元及134.4元。
康方生物(09926.HK)也連續第二天反覆創上市新高,該股今早隨大市低開報34.6元獲承接,掉頭突破周三盤中所創上市高位35.5元,最高見37.45元,半日收36.9元,逆市續升5.3%,成交265萬股。
康方是一家臨床階段生物製藥公司,致力於自主發現、開發及商業化首創及同類最佳療法,並專注於滿足腫瘤、免疫及其他治療領域在全球未決醫療需求。股份於今年4月24日以每股16.18元上市。康方本月中先後公布自主研發新藥AK120(用於特應性皮炎及哮喘等過敏性疾病)及AK109(用於晚期實體瘤)均已完成首例患者入組給藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.